Chondrex: New marker of joint disease

Sheryl Harvey, Michael Weisman, James Robert O'Dell, Tonya Scott, Mindy Krusemeier, Jill Visor, Cathy Swindlehurst

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

Chondrex, a major secretory protein of human chondrocytes and synovial fibroblasts, is increased in serum of patients with joint and cartilage disease. We have developed a sandwich-type ELISA for quantifying chondrex in serum. The interassay CVs were 2.8-3.7% and the average within-run and total CVs were 3.6% and 5.4%, respectively. The limit of detectability by linear dilution was 20 μg/L, recovery upon dilution was 102% ± 5%, and analytical recovery (of added analyte) was 98% ± 11%. The reference interval (central 90% interval) for chondrex in healthy adults was 25-95 μg/L. Chondrex values for patients with active rheumatoid arthritis or osteoarthritis were significantly greater than in healthy adults, inactive rheumatoid arthritis patients, and diabetes patients (P <0.05). In patients treated with disease- modifying antirheumatic drug therapy, decreasing chondrex values reflected the clinical improvement observed in responders, whereas the values were maintained or increased in nonresponders. In conclusion, chondrex may be a useful marker in the clinical investigation of arthritis.

Original languageEnglish (US)
Pages (from-to)509-516
Number of pages8
JournalClinical Chemistry
Volume44
Issue number3
StatePublished - Apr 8 1998

Fingerprint

Joint Diseases
Dilution
Rheumatoid Arthritis
Cartilage Diseases
Drug therapy
Recovery
Antirheumatic Agents
Cartilage
Fibroblasts
Medical problems
Chondrocytes
Serum
Osteoarthritis
Arthritis
human CHI3L1 protein
Biomarkers
Enzyme-Linked Immunosorbent Assay
Drug Therapy
Proteins

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Harvey, S., Weisman, M., O'Dell, J. R., Scott, T., Krusemeier, M., Visor, J., & Swindlehurst, C. (1998). Chondrex: New marker of joint disease. Clinical Chemistry, 44(3), 509-516.

Chondrex : New marker of joint disease. / Harvey, Sheryl; Weisman, Michael; O'Dell, James Robert; Scott, Tonya; Krusemeier, Mindy; Visor, Jill; Swindlehurst, Cathy.

In: Clinical Chemistry, Vol. 44, No. 3, 08.04.1998, p. 509-516.

Research output: Contribution to journalArticle

Harvey, S, Weisman, M, O'Dell, JR, Scott, T, Krusemeier, M, Visor, J & Swindlehurst, C 1998, 'Chondrex: New marker of joint disease', Clinical Chemistry, vol. 44, no. 3, pp. 509-516.
Harvey S, Weisman M, O'Dell JR, Scott T, Krusemeier M, Visor J et al. Chondrex: New marker of joint disease. Clinical Chemistry. 1998 Apr 8;44(3):509-516.
Harvey, Sheryl ; Weisman, Michael ; O'Dell, James Robert ; Scott, Tonya ; Krusemeier, Mindy ; Visor, Jill ; Swindlehurst, Cathy. / Chondrex : New marker of joint disease. In: Clinical Chemistry. 1998 ; Vol. 44, No. 3. pp. 509-516.
@article{45b9cb57f03440109fe3bfd259a161ab,
title = "Chondrex: New marker of joint disease",
abstract = "Chondrex, a major secretory protein of human chondrocytes and synovial fibroblasts, is increased in serum of patients with joint and cartilage disease. We have developed a sandwich-type ELISA for quantifying chondrex in serum. The interassay CVs were 2.8-3.7{\%} and the average within-run and total CVs were 3.6{\%} and 5.4{\%}, respectively. The limit of detectability by linear dilution was 20 μg/L, recovery upon dilution was 102{\%} ± 5{\%}, and analytical recovery (of added analyte) was 98{\%} ± 11{\%}. The reference interval (central 90{\%} interval) for chondrex in healthy adults was 25-95 μg/L. Chondrex values for patients with active rheumatoid arthritis or osteoarthritis were significantly greater than in healthy adults, inactive rheumatoid arthritis patients, and diabetes patients (P <0.05). In patients treated with disease- modifying antirheumatic drug therapy, decreasing chondrex values reflected the clinical improvement observed in responders, whereas the values were maintained or increased in nonresponders. In conclusion, chondrex may be a useful marker in the clinical investigation of arthritis.",
author = "Sheryl Harvey and Michael Weisman and O'Dell, {James Robert} and Tonya Scott and Mindy Krusemeier and Jill Visor and Cathy Swindlehurst",
year = "1998",
month = "4",
day = "8",
language = "English (US)",
volume = "44",
pages = "509--516",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "3",

}

TY - JOUR

T1 - Chondrex

T2 - New marker of joint disease

AU - Harvey, Sheryl

AU - Weisman, Michael

AU - O'Dell, James Robert

AU - Scott, Tonya

AU - Krusemeier, Mindy

AU - Visor, Jill

AU - Swindlehurst, Cathy

PY - 1998/4/8

Y1 - 1998/4/8

N2 - Chondrex, a major secretory protein of human chondrocytes and synovial fibroblasts, is increased in serum of patients with joint and cartilage disease. We have developed a sandwich-type ELISA for quantifying chondrex in serum. The interassay CVs were 2.8-3.7% and the average within-run and total CVs were 3.6% and 5.4%, respectively. The limit of detectability by linear dilution was 20 μg/L, recovery upon dilution was 102% ± 5%, and analytical recovery (of added analyte) was 98% ± 11%. The reference interval (central 90% interval) for chondrex in healthy adults was 25-95 μg/L. Chondrex values for patients with active rheumatoid arthritis or osteoarthritis were significantly greater than in healthy adults, inactive rheumatoid arthritis patients, and diabetes patients (P <0.05). In patients treated with disease- modifying antirheumatic drug therapy, decreasing chondrex values reflected the clinical improvement observed in responders, whereas the values were maintained or increased in nonresponders. In conclusion, chondrex may be a useful marker in the clinical investigation of arthritis.

AB - Chondrex, a major secretory protein of human chondrocytes and synovial fibroblasts, is increased in serum of patients with joint and cartilage disease. We have developed a sandwich-type ELISA for quantifying chondrex in serum. The interassay CVs were 2.8-3.7% and the average within-run and total CVs were 3.6% and 5.4%, respectively. The limit of detectability by linear dilution was 20 μg/L, recovery upon dilution was 102% ± 5%, and analytical recovery (of added analyte) was 98% ± 11%. The reference interval (central 90% interval) for chondrex in healthy adults was 25-95 μg/L. Chondrex values for patients with active rheumatoid arthritis or osteoarthritis were significantly greater than in healthy adults, inactive rheumatoid arthritis patients, and diabetes patients (P <0.05). In patients treated with disease- modifying antirheumatic drug therapy, decreasing chondrex values reflected the clinical improvement observed in responders, whereas the values were maintained or increased in nonresponders. In conclusion, chondrex may be a useful marker in the clinical investigation of arthritis.

UR - http://www.scopus.com/inward/record.url?scp=0031911418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031911418&partnerID=8YFLogxK

M3 - Article

C2 - 9510855

AN - SCOPUS:0031911418

VL - 44

SP - 509

EP - 516

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 3

ER -